Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas

Charles Yates, D. Bradley Welling, Long Sheng Chang

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Vestibular schwannomas (VSs) are benign nerve sheath tumors that are frequently seen along with other nervous system tumors in patients with Neurofibromatosis type 2 (NF2). Current management options include observation by magnetic resonance imaging (MRI), surgical excision, and stereotactic radiation. However, complications from treatment, such as hearing loss, facial weakness, dizziness, intracranial bleeding, and stroke, remain major concerns. In addition, radiation treatment may cause malignant transformation and/or growth acceleration of the tumors. Thus, development of a medical therapy for the treatment of NF2-associated tumors is urgently needed. Recent studies provide new insight into the role of merlin, the NF2 tumor suppressor gene product that is frequently inactivated in VSs, and the signaling pathways that are deregulated during VS tumorigenesis. Several in vitro and in vivo models for NF2-associated tumors have been developed and are utilities for therapeutic testing. A number of exciting research studies on therapeutic interventions for VS have been initiated and show promising results. Hopefully, some of the drugs or pathway-specific inhibitors will prove effective and become alternatives to the current treatment options.

Original languageEnglish (US)
Title of host publicationAdvances in Neurofibromatosis Research
PublisherNova Science Publishers, Inc.
Pages221-236
Number of pages16
ISBN (Print)9781613246610
StatePublished - 2012
Externally publishedYes

Fingerprint

Neurofibromatosis 2
Acoustic Neuroma
Research
Therapeutics
Nerve Sheath Neoplasms
Nervous System Neoplasms
Radiation
Neoplasms
Dizziness
Tumor Suppressor Genes
Hearing Loss
Carcinogenesis
Stroke
Magnetic Resonance Imaging
Observation
Hemorrhage
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yates, C., Welling, D. B., & Chang, L. S. (2012). Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas. In Advances in Neurofibromatosis Research (pp. 221-236). Nova Science Publishers, Inc..

Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas. / Yates, Charles; Welling, D. Bradley; Chang, Long Sheng.

Advances in Neurofibromatosis Research. Nova Science Publishers, Inc., 2012. p. 221-236.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yates, C, Welling, DB & Chang, LS 2012, Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas. in Advances in Neurofibromatosis Research. Nova Science Publishers, Inc., pp. 221-236.
Yates C, Welling DB, Chang LS. Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas. In Advances in Neurofibromatosis Research. Nova Science Publishers, Inc. 2012. p. 221-236
Yates, Charles ; Welling, D. Bradley ; Chang, Long Sheng. / Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas. Advances in Neurofibromatosis Research. Nova Science Publishers, Inc., 2012. pp. 221-236
@inbook{fe06b00013944c9e86572fd8b49a6435,
title = "Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas",
abstract = "Vestibular schwannomas (VSs) are benign nerve sheath tumors that are frequently seen along with other nervous system tumors in patients with Neurofibromatosis type 2 (NF2). Current management options include observation by magnetic resonance imaging (MRI), surgical excision, and stereotactic radiation. However, complications from treatment, such as hearing loss, facial weakness, dizziness, intracranial bleeding, and stroke, remain major concerns. In addition, radiation treatment may cause malignant transformation and/or growth acceleration of the tumors. Thus, development of a medical therapy for the treatment of NF2-associated tumors is urgently needed. Recent studies provide new insight into the role of merlin, the NF2 tumor suppressor gene product that is frequently inactivated in VSs, and the signaling pathways that are deregulated during VS tumorigenesis. Several in vitro and in vivo models for NF2-associated tumors have been developed and are utilities for therapeutic testing. A number of exciting research studies on therapeutic interventions for VS have been initiated and show promising results. Hopefully, some of the drugs or pathway-specific inhibitors will prove effective and become alternatives to the current treatment options.",
author = "Charles Yates and Welling, {D. Bradley} and Chang, {Long Sheng}",
year = "2012",
language = "English (US)",
isbn = "9781613246610",
pages = "221--236",
booktitle = "Advances in Neurofibromatosis Research",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Research advances in therapeutics for neurofibromatosis type 2-associated vestibular schwannomas

AU - Yates, Charles

AU - Welling, D. Bradley

AU - Chang, Long Sheng

PY - 2012

Y1 - 2012

N2 - Vestibular schwannomas (VSs) are benign nerve sheath tumors that are frequently seen along with other nervous system tumors in patients with Neurofibromatosis type 2 (NF2). Current management options include observation by magnetic resonance imaging (MRI), surgical excision, and stereotactic radiation. However, complications from treatment, such as hearing loss, facial weakness, dizziness, intracranial bleeding, and stroke, remain major concerns. In addition, radiation treatment may cause malignant transformation and/or growth acceleration of the tumors. Thus, development of a medical therapy for the treatment of NF2-associated tumors is urgently needed. Recent studies provide new insight into the role of merlin, the NF2 tumor suppressor gene product that is frequently inactivated in VSs, and the signaling pathways that are deregulated during VS tumorigenesis. Several in vitro and in vivo models for NF2-associated tumors have been developed and are utilities for therapeutic testing. A number of exciting research studies on therapeutic interventions for VS have been initiated and show promising results. Hopefully, some of the drugs or pathway-specific inhibitors will prove effective and become alternatives to the current treatment options.

AB - Vestibular schwannomas (VSs) are benign nerve sheath tumors that are frequently seen along with other nervous system tumors in patients with Neurofibromatosis type 2 (NF2). Current management options include observation by magnetic resonance imaging (MRI), surgical excision, and stereotactic radiation. However, complications from treatment, such as hearing loss, facial weakness, dizziness, intracranial bleeding, and stroke, remain major concerns. In addition, radiation treatment may cause malignant transformation and/or growth acceleration of the tumors. Thus, development of a medical therapy for the treatment of NF2-associated tumors is urgently needed. Recent studies provide new insight into the role of merlin, the NF2 tumor suppressor gene product that is frequently inactivated in VSs, and the signaling pathways that are deregulated during VS tumorigenesis. Several in vitro and in vivo models for NF2-associated tumors have been developed and are utilities for therapeutic testing. A number of exciting research studies on therapeutic interventions for VS have been initiated and show promising results. Hopefully, some of the drugs or pathway-specific inhibitors will prove effective and become alternatives to the current treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84885023511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885023511&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84885023511

SN - 9781613246610

SP - 221

EP - 236

BT - Advances in Neurofibromatosis Research

PB - Nova Science Publishers, Inc.

ER -